BioCardia

BioCardia's CardiAMP Cell Therapy demonstrated an 82% reduction in angina episodes and 80-second improvement in exercise tolerance at six months in patients with chronic myocardial ischemia.

BioCardia and CART-Tech have entered into an exclusive development and commercialization agreement for Heart3D Fusion Imaging, a system that enhances 2D x-ray images by fusing them with 3D anatomical heart models from MRI and CT scans.

BioCardia submitted its CardiAMP autologous cell therapy to Japan's PMDA for clinical consultation, marking a significant step toward potential regulatory approval in the key Japanese market.

BioCardia reported positive safety and meaningful benefits from their CardiAMP cardiac cell therapy for heart failure patients, addressing a significant unmet clinical need despite missing the primary endpoint in their previous trial.

BioCardia has completed enrollment and dosing of the low-dose cohort in its CardiALLO Phase I/II trial, targeting ischemic heart failure patients with elevated markers of heart stress and inflammation.

The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.

BioCardia has commercially launched its Morph DNA steerable introducer, designed for enhanced control in biotherapeutic delivery, particularly in cell-therapy clinical trials.

BioCardia's CardiAMP HF Phase 3 trial results will be presented at the American College of Cardiology (ACC) 2025 Scientific Sessions.

Genprex presented positive preclinical data for Reqorsa, a gene therapy targeting Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma, showing increased TUSC2 uptake in tumor cells.

Shuttle Pharmaceuticals has enrolled the first patient in its Phase 2 clinical trial of ropidoxuridine for glioblastoma at the UVA Cancer Center.